A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine

Publication date: Available online 10 August 2017
Source:Vaccine
Author(s): Yu-Feng Cao, Hong Tao, Yue-Mei Hu, Cheng-Bo Shi, Xing Wu, Qi Liang, Chun-Ping Chi, Li Li, Zheng-Lun Liang, Ji-Hong Meng, Feng-Cai Zhu, Zhao-Hui Liu, Xin-Ping Wang
BackgroundThis study aimed to evaluate the safety and tolerability for variable dosages of a novel hepatitis E vaccine p179.MethodsThe randomized open-label parallel control phase 1 clinical trial enrolled 120 eligible participants aged 16–65years in Jiangsu Province, China. The experimental groups were randomized to receive different dosages of 20μg, 30μg, and 40μg Hepatitis E Virus (HEV) p179 vaccines, with the 30μgHEV vaccine p239 Hecolin as control, and vaccinated at 0, 1 and 6month intervals. Participants were observed for solicited local and systemic adverse reactions (ARs) occurring within 7days after each vaccination, and any serious adverse events (SAEs) occurring within 6months post-vaccination. Blood samples were collected from participants 3days before and after each injection, to determine the blood routine and serum biochemical indexes.ResultsThe solicited local ARs incidence in experimental groups were significantly lower than that of the control group (P=0.027). The difference between solicited total and systemic ARs incidence of experimental groups and the control group were not significant (P>0.05). Similar patterns were observed when the analyses were performed on the group having ARs of varying grades and symptoms. All changes in blood biochemical indexes and routine blood tests before and after different vaccinations were mild (grade 1) or moderate (grade 2), and the difference in experimental groups and the control group were not statistically significant. No vaccine related SAEs occurred in any of the subjects during the study.ConclusionThree different dosages of HEV p179 vaccine were deemed safe and well tolerated. No vaccine-associated SAEs were identified, and the 30μg dosage formulation was selected for further investigation for efficacy.Clinical trials registration number: 2012L01657.



http://ift.tt/2wAMxnF